论文信息 - Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial - 字舞流文

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

R. Schiffmann | R. Colvin | O. Goker-Alpan | K. Nicholls | D. Hughes | L. Barisoni | S. Boyadjiev | M. Atta | M. Holida | G. Maegawa | P. Giraldo | D. Gonzalez | E. Brill‐Almon | B. Rup | A. Tuffaha | Sari Alon | R. Chertkoff | A. Paz | M. R. Charney | C. Jennette | Mali Szlaifer | Einat Brill‐Almon | Martha R. Charney